Conditional transgene expression in the heart

Circulation Research

Volumn 79, Issue 4, 1996, Pages 691-697

  Yu, Zhihui ^a   Redfern, Charles S ^b   Fishman, Glenn I ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

binary; conditional; heart; tetracycline; transgenic

Indexed keywords

LUCIFERASE;

ANIMAL TISSUE; ARTICLE; DNA FLANKING REGION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; HEART MUSCLE CELL; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN STABILITY; REPORTER GENE; TISSUE SPECIFICITY; TRANSACTIVATION; TRANSGENE;

EID: 0029816480     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.79.4.691     Document Type: Article

References (42)

1. Camper SA, Saunders TL, Kendall SK, Keri RA, Seasholtz AF, Gordon DF, Birkmeier TS, Keegan CE, Karolyi IJ, Roller ML, et al. Implementing transgenic and embryonic stem cell technology to study gene expression, cell-cell interactions and gene function. Biol Reprod. 1995;52:246-257.
2. Iannaccone PM, Scarpelli DG. Exploring pathogenetic mechanisms using transgenic animals. Ann Med. 1993;25:131-138.
3. Metsaranta M, Vuorio E. Transgenic mice as models for heritable diseases. Ann Med. 1992;24:117-120.
4. Chien KR. Recent advances in the molecular biology of cardiac growth and hypertrophy: of mouse and man. Cardiologia. 1992;37: 95-103.
5. Chien KR. Molecular advances in cardiovascular biology. Science. 1993;260:916-917.
6. Chien KR. Cardiac muscle diseases in genetically engineered mice: evolution of molecular physiology. Am J Physiol. 1995;269:H755-H766.
7. Field LJ. Transgenic mice in cardiovascular research. Annu Rev Physiol. 1993;55:97-114.
8. Lin MC, Rockman HA, Chien KR. Heart and lung disease in engineered mice. Nat Med. 1995;1:749-751.
9. Paigen B, Plump AS, Rubin EM. The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr Opin Lipidol. 1994; 5:258-264.
10. Field LJ. Atrial natriuretic factor-SV40 T antigen transgenes produce tumors and cardiac arrhythmias in mice. Science, 1988;239:1029-1033.
11. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 1995;270:23173-23178.
12. Hunter JJ, Zhu H, Lee KJ, Kubalak S, Chien KR. Targeting gene expression to specific cardiovascular cell types in transgenic mice. Hypertension. 1993;22:608-617.
13. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Bond RA, Lefkowitz RJ. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science. 1994;264:582-586.
14. Rindt H, Subramaniam A, Robbins J. An in vivo analysis of transcriptional elements in the mouse alpha-myosin heavy chain gene promoter. Transgenic Res. 1995;4:397-405.
15. Rockman HA, Ono S, Ross RS, Jones LR, Karimi M, Bhargava V, Ross JJ, Chien KR. Molecular and physiological alterations in murine ventricular dysfunction. Proc Natl Acad Sci USA. 1994;91:2694-2698.
16. Subramaniam A, Jones WK, Gulick J, Wen S, Neumann J, Robbins J. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 1991;266:24613-24620.
17. Braun T, Rudnicki MA, Arnold HH, Jaenisch R. Targeted inactivation of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal death. Cell. 1992;71:369-382.
18. Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN. Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature. 1993;364: 501-506.
19. Rudnicki MA, Braun T, Hinuma S, Jaenisch R, Inactivation of MyoD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. Cell. 1992;71:383-390.
20. Rudnicki MA, Jaenisch R. The MyoD family of transcription factors and skeletal myogenesis. Bioessays. 1995;17:203-209.
21. Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH, Jaenisch R. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell. 1993;75:1351-1359.
22. Venuti JM, Morris JH, Vivian JL, Olson EN, Klein WH. Myogenin is required for late but not early aspects of myogenesis during mouse development. J Cell Biol 1995;128:563-576.
23. Hanks M, Wurst W, Anson-Cartwright L, Auerbach AB, Joyner AL. Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2, Science. 1995;269:679-682.
24. Wang Y, Schnegelsberg P, Dausman J, Jaenisch R, Functional redundancy of the muscle-specific transcription factors Myf5 and myogenin. Nature. 1996;379:823-825.
25. Baim S, Labow M, Levine A, Shenk T. A chimeric mammalian transactivator based on the lac repressor that is regulated by temperature and isopropyl-D-thiogalactopyranoside. Proc Natl Acad Sci USA. 1991;88:5072-5076.
26. Fishman G. Conditional transgenics. Trends Cardiovasc Med. 1996;5:211-217,
27. Ornitz D, Moreadith R, Leder P. Binary system for regulating transgene expression in mice: targeting int-2 gene expression with yeast GAL4/UAS control elements. Proc Natl Acad Sci USA. 1991;88: 698-702.
28. Ringold G, Regulation of mouse mammary tumor virus gene expression by glucocorticoid hormones. Curr Top Microbiol Immunol. 1996;106:79-103.
29. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89:5547-5551.
30. Passman RS, Fishman GI. Regulated expression of foreign genes in vivo after germline transfer J Clin Invest. 1994;94:2421-2425.
31. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci U S A. 1994;91:9302-9306.
32. Efrat S, Fusco-DeMane D, Lemberg H, al Emran O, Wang X. Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc Natl Acad Sci U S A. 1995;92:3576-3580.
33. Fishman GI, Kaplan ML, Buttrick PM. Tetracycline-regulated cardiac gene expression in vivo. J Clin Invest. 1994;93:1864-1868.
34. Jones WK, Sanchez A, Robbins J. Murine pulmonary myocardium: developmental analysis of cardiac gene expression. Dev Dyn. 1994; 200:117-128.
35. Thompson J, Hayes L, Lloyd D. Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene. 1991;103:171-177.
36. 2+ sensitivity of tension in mouse cardiac myocytes expressing skeletal troponin C. J Physiol. 1995; 483:131-139.
37. Reuter G, Spierer P, Position effect variegation and chromatin proteins. Bioessays. 1992;14:605-612.
38. Fuller SJ, Chien KR. Genetic engineering of cardiac muscle cells: in vitro and in vivo. Genet Eng. 1994;16:17-31.
39. Robbins J. Gene targeting: the precise manipulation of the mammalian genome. Circ Res. 1993;73:3-9.
40. Grupp IL, Subramaniam A, Hewett TE, Robbins J, Grupp G, Comparison of normal, hypodynamic, and hyperdynamic mouse hearts using isolated work-performing heart preparations. Am J Physiol. 1993;265:H1401-H1410.
41. Hewett TE, Grupp IL, Grupp G, Robbins J. α-Skeletal actin is associated with increased contractility in the mouse heart. Circ Res. 1994;74:740-746.
42. Ng WA, Grupp IL, Subramaniam A, Robbins J. Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart. Circ Res. 1991;68:1742-1750.